Feb 14, 2013, 02.09 PM | Source: Reuters
Shares in Dr Reddy's Laboratories fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day
Margins are also expected to see significant erosion, several dealers add.
Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at Rs 26.03 compared with mean estimate of Rs 27.89.
In an interview with CNBC-TV18, Rajesh Kothari of
Sanjiv Bhasin of IIFL recommends buying Dr Reddy's
Dr Reddy's Laboratories has successfully completed